ALDX Aldeyra Therapeutics, Inc.
$0.64▼ -0.08%
Healthcare
Other
After hours
$0.65▲ +0.62%
Oct 27, 4:16 PM ET
Volume 991.8K
Avg Volume (10D) 1.15M
Key Metrics & Fundamentals
Market Cap
$38.68M
P/E Ratio
–
Div Yield
0.00%
52W Range
0.60 - 5.93
% vs 50 MA
-46.60%
% vs 200 MA
-72.50%
RSI-14
25.4
MACD Histogram
+0.0000
Beta (1Y vs SPY)
1.21
Free Cash Flow
-$4.61M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$5.38M
COGS
–
Operating Exp
$5.85M
Operating Income
-$5.85M
EBIT
-$5.85M
Pretax Income
-$5.45M
Net Income
-$5.45M
EPS (Diluted)
-0.09
Price & Volume History
Loading chart…
Recent News
RARE's Fayuvi Approval Spurs Second PRV Sale Worth $203M in a Week
Zacks · Oct 15, 2026 9:33 AM ET
Here's Why You Should Add ANRO Stock to Your Portfolio Now
Zacks · Oct 14, 2026 8:59 AM ET
Syndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary Goal
Zacks · Oct 14, 2026 8:52 AM ET
Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why
Zacks · Oct 12, 2026 11:24 AM ET
PMVP Stock Rises 19% in 3 Months: Here's What You Need to Know
Zacks · Oct 12, 2026 10:55 AM ET
argenx Meets Primary Endpoint in Phase II Celiac Disease Study
Zacks · Oct 9, 2026 12:55 PM ET
EDIT Set to Begin First-in-Human Study in Hypercholesterolemia
Zacks · Oct 9, 2026 10:53 AM ET
Here's Why You Should Add LPCN Stock to Your Portfolio Now
Zacks · Oct 8, 2026 9:57 AM ET
Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash
Zacks · Oct 8, 2026 9:49 AM ET
ETON Stock Surges 108% in Six Months: Here's What You Need to Know
Zacks · Oct 7, 2026 11:08 AM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See ALDX's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.